NCT07083349View on ClinicalTrials.gov

NK510 Cell Therapy for Refractory Systemic Lupus Erythematosus

NANot yet recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

September 1, 2027

Study Completion Date

September 1, 2027

Conditions
Refractory Systemic Lupus Erythematosus
Interventions
DRUG

NK510 : allogeneic genetic modified NK

NK510 is an allogeneic genetic modification of NK cell. NK510 will be administered at a dose of 4x10\^7 NK/kg, 8x10\^7 NK/kg and 1.2x10\^8 NK/kg by a dose-escalation design and administered IV.

All Listed Sponsors
collaborator

The First Affiliated Hospital of Anhui Medical University

OTHER

lead

Base Therapeutics (Shanghai) Co., Ltd.

INDUSTRY